PATH | VRL
Menu

Evaluation of Meningitis Surveillance Before Introduction of Serogroup A Meningococcal Conjugate Vaccine—Burkina Faso and Mali

Before the 2010 to 2011 introduction of the first serogroup A meningococcal conjugate vaccine developed solely for Africa (MenAfriVac), evaluations of the existing meningitis surveillance in Burkina Faso and Mali were conducted to assess the capacity for case-based surveillance. This article, published in Morbidity and Mortality Weekly Report, describes the results of those evaluations, which found that surveillance infrastructures were strong but opportunities existed for improving data management, handling of specimens shipped to reference laboratories, and laboratory capacity for confirming cases. These findings underscore the need to evaluate surveillance before vaccine introduction so that activities to strengthen surveillance are tailored to a country's needs and capacities.

Author: US Centers for Disease Control and Prevention

Published: 2012

» Visit web page (English)

(Located at www.cdc.gov)

Resource types: Newsletter/article

Diseases/vaccines: Meningococcus

Topics: Disease burden and surveillance, Disease/vaccine specific information

Regions: Africa